Your browser doesn't support javascript.
loading
Immune hallmarks of rheumatoid arthritis management: A brief review.
Fonseca Peixoto, Rephany; Ewerton Maia Rodrigues, Carlos; Henrique de Sousa Palmeira, Pedro; Cézar Comberlang Queiroz Davis Dos Santos, Fernando; Keesen de Souza Lima, Tatjana; de Sousa Braz, Alessandra.
Afiliação
  • Fonseca Peixoto R; Laboratory of Immunology of Infectious Diseases, Department of Cellular and Molecular Biology, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil.
  • Ewerton Maia Rodrigues C; Post­Graduate Program in Medical Sciences, Medical School, University of Fortaleza (Unifor), Fortaleza, Brazil; Department of Internal Medicine, Federal University of Ceará, Brazil. Electronic address: carlosewerton@unifor.br.
  • Henrique de Sousa Palmeira P; Laboratory of Immunology of Infectious Diseases, Department of Cellular and Molecular Biology, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil.
  • Cézar Comberlang Queiroz Davis Dos Santos F; Laboratory of Immunology of Infectious Diseases, Department of Cellular and Molecular Biology, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil.
  • Keesen de Souza Lima T; Laboratory of Immunology of Infectious Diseases, Department of Cellular and Molecular Biology, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil.
  • de Sousa Braz A; Medical Sciences Center, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil.
Cytokine ; 158: 156007, 2022 10.
Article em En | MEDLINE | ID: mdl-35985174
The purpose of this review was to examine current evidence on immunomodulation mediated by conventional drugs and the use of novel biological agents for the treatment of rheumatoid arthritis (RA). Currently, treatment is focused on maximizing quality of life through sustained clinical remission and/or attenuating disease activity. To do so, disease-modifying antirheumatic drugs, especially methotrexate, are used alone or in combination with other drugs, including leflunomide, biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs). The most recent strategies modulate the immune response of the individual RA patient using tsDMARDs such as JAK inhibitors and bDMARDs such as ig-CTLA-4, anti- IL6R, anti-TNF-α and anti-CD20. To better understand current immunopharmacological interventions, we also looked at documented mechanisms of RA-mediated immunomodulation, highlighting perspectives potentially boosting RA treatment.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Produtos Biológicos / Antirreumáticos Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Cytokine Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Produtos Biológicos / Antirreumáticos Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Cytokine Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido